Features and risk factors in chronic hepatitis B patients comorbid with metabolic associated fatty liver disease

Qing ZHAO; Lihui ZHANG; Sutong LIU; Dongfang SHANG; Qiang ZHANG; Wenxia ZHAO

doi:10.12449/JCH251212

Volume 41 Issue 12

Dec. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(12): 2512-2519

PDF( 783 KB)

Features and risk factors in chronic hepatitis B patients comorbid with metabolic associated fatty liver disease

DOI: 10.12449/JCH251212

1.
Department of Gastroenterology，The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450000，China
2.
The First Clinical Medical College of Henan University of Chinese Medicine，Zhengzhou 450000，China

Research funding:

National Natural Science Foundation of China Youth Science Foundation Project (82205086);

National Famous Traditional Chinese Medicine Inheritance Studio Construction Project (Chinese Medicine Office Human Education Letter ［2022］ 245);

Special Subject of Scientific Research on Traditional Chinese Medicine in Henan Province (2022JDZX031);

Special Subject of Scientific Research on Traditional Chinese Medicine in Henan Province (2023ZXZX1092)

More Information

Corresponding author: ZHAO Wenxia， zhao-wenxia@163.com （ORCID： 0000-0001-6666-9469）
Received Date: 2025-07-07
Accepted Date: 2025-08-08
Published Date: 2025-12-25

Abstract

Abstract

Objective To investigate the comorbidity features of chronic hepatitis B （CHB） patients comorbid with metabolic associated fatty liver disease （MAFLD）， to analyze its risk factors， and to provide a basis for clinical prevention and treatment. Methods A total of 92 patients who were diagnosed with CHB in The First Affiliated Hospital of Henan University of Chinese Medicine from January 2023 to December 2024 were enrolled and divided into CHB+MAFLD group with 52 patients and CHB group with 40 patients. Related data were collected from all patients， including general information， medical history， serum biochemical parameters， virological testing indicators， and FibroScan results. The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between two groups； the chi-square test or the Fisher’s exact test was used for comparison of categorical data between two groups； the binary Logistic regression analysis was used to investigate the risk factors for CHB comorbid with MAFLD. Results There were significant differences between the two groups in sex， body mass index （BMI）， antiviral therapy， duration of antiviral medication， the preference for high-fat diet or spicy foods， and the levels of alanine aminotransferase， uric acid （UA）， triglyceride （TG）， high-density lipoprotein cholesterol， and controlled attenuation parameter （all P<0.05）. The univariate regression analysis showed that male sex， preference for high-fat diet and spicy foods， antiviral therapy， antiviral medication for >5 years， BMI ≥24 kg/m²， UA >357 μmol/L， and TG >1.70 mmol/L were associated with comorbidity with MAFLD （all P <0.05）； the multivariate regression analysis showed that antiviral medication >5 years （odds ratio ［OR］=9.38， 95% confidence interval ［CI］： 2.28 — 38.60， P=0.002）， BMI ≥24 kg/m² （OR=5.60， 95%CI： 1.75 — 17.88， P=0.004）， and TG >1.70 mmol/L （OR=4.08， 95%CI： 1.17 — 14.31， P=0.028） were independent risk factors for CHB patients comorbid with MAFLD. Conclusion CHB comorbid with MAFLD is the result of metabolic disorders and long-term antiviral therapy. Clinical management should be enhanced for CHB patients with long-term antiviral therapy， overweight/obesity， and hypertriglyceridemia， and targeted screening and intervention strategies should be implemented.
- Hepatitis B， Chronic,
- Metabolic Associated Fatty Liver Disease,
- Multiple Chronic Conditions,
- Risk Factors

FullText(HTML)

References(42)

References

[1]	WHO. Global hepatitis report 2024: Action for access in low-and middle-income countries[EB/OL].( 2024-04-09)[ 2025-01-03]. https://www.who.int/publications/i/item/9789240091672. https: //www.who.int/publications/i/item/9789240091672
[2]	SHAN S, JIA JD. Advances and challenges in the treatment of chronic hepatitis B in China[J]. J Clin Hepatol, 2025, 41( 2): 205- 209. DOI: 10.12449/JCH250202. 单姗, 贾继东. 中国慢性乙型肝炎治疗的进展与挑战[J]. 临床肝胆病杂志, 2025, 41( 2): 205- 209. DOI: 10.12449/JCH250202.
[3]	YOUNOSSI ZM, STEPANOVA M, YOUNOSSI Y, et al. Epidemiology of chronic liver diseases in the USA in the past three decades[J]. Gut, 2020, 69( 3): 564- 568. DOI: 10.1136/gutjnl-2019-318813.
[4]	ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73( 1): 202- 209. DOI: 10.1016/j.jhep.2020.03.039.
[5]	ZONG TN. Analysis of detection rate and related factors of metabolic associated fatty liver disease in physical examination population[D]. Yan’an: Yan’an University, 2023. DOI: 10.27438/d.cnki.gyadu.2023.001023. 宗廷妮. 体检人群中代谢相关脂肪性肝病的检出率及相关因素[D]. 延安: 延安大学, 2023. DOI: 10.27438/d.cnki.gyadu.2023.001023.
[6]	YANG M, WEI L. Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia[J]. Liver Int, 2022, 42( 9): 1981- 1990. DOI: 10.1111/liv.15252.
[7]	ZHENG Q, ZOU BY, WU YK, et al. Systematic review with meta-analysis: Prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B[J]. Aliment Pharmacol Ther, 2021, 54( 9): 1100- 1109. DOI: 10.1111/apt.16595.
[8]	CHOI HSJ, BROUWER WP, ZANJIR WMR, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B[J]. Hepatology, 2020, 71( 2): 539- 548. DOI: 10.1002/hep.30857.
[9]	HAN CL, TIAN BW, YANG CC, et al. The association of fatty liver and risk of hepatocellular carcinoma in HBV or HCV infected individuals: A systematic review and meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2023, 17( 2): 189- 198. DOI: 10.1080/17474124.2023.2166930.
[10]	CHO H, CHANG Y, LEE JH, et al. Radiologic nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with suppressed chronic hepatitis B[J]. J Clin Gastroenterol, 2020, 54( 7): 633- 641. DOI: 10.1097/MCG.0000000000001217.
[11]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. J Pract Hepatol, 2023, 26( 3): S18- S39. DOI: 10.3969/j.issn.1672-5069.2023.03.040. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志, 2023, 26( 3): S18- S39. DOI: 10.3969/j.issn.1672-5069.2023.03.040.
[12]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of metabolic dysfunction-associated(non-alcoholic) fatty liver disease(Version 2024)[J]. J Pract Hepatol, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163. 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163.
[13]	MAN S, DENG YH, MA Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: A nationwide study with 5.7 million adults in China[J]. Gastroenterology, 2023, 165( 4): 1025- 1040. DOI: 10.1053/j.gastro.2023.05.053.
[14]	XU H, FANG D, ZHOU WH, et al. A retrospective cohort study of the Chinese visceral adiposity index and risk of fatty liver[J]. Chin Gen Pract, 2025, 28( 11): 1336- 1341. DOI: 10.12114/j.issn.1007-9572.2024.0408. 徐浩, 方达, 周卫红, 等. 中国内脏脂肪指数与脂肪肝发生风险的回顾性队列研究[J]. 中国全科医学, 2025, 28( 11): 1336- 1341. DOI: 10.12114/j.issn.1007-9572.2024.0408.
[15]	SHI J, GE ZH, REN YT, et al. Associations between body composition and insulin resistance in different gender communities[J]. Mod Prev Med, 2024, 51( 12): 2253- 2261. DOI: 10.20043/j.cnki.MPM.202403067. 施俊, 葛志豪, 任雅婷, 等. 不同性别社区人群体成分与胰岛素抵抗关联研究[J]. 现代预防医学, 2024, 51( 12): 2253- 2261. DOI: 10.20043/j.cnki.MPM.202403067.
[16]	HE TF, YAN WY, LIU KG. Research progress on the influence of obesity on serology of metabolic fatty liver disease[J]. J Clin Intern Med, 2023, 40( 11): 788- 790. DOI: 10.3969/j.issn.1001-9057.2023.11.023. 何腾飞, 闫婉玉, 刘凯歌. 肥胖对代谢相关脂肪性肝病血清学影响的研究进展[J]. 临床内科杂志, 2023, 40( 11): 788- 790. DOI: 10.3969/j.issn.1001-9057.2023.11.023.
[17]	WANG JJ, SU YJ. Relationship between obesity and nonalcoholic fatty liver disease and its pathogenesis[J]. Chin J Clin, 2020, 48( 1): 6- 9. DOI: 10.3969/j.issn.2095-8552.2020.01.003. 王京京, 苏云娟. 肥胖与非酒精性脂肪性肝病的关系及发病机制[J]. 中国临床医生杂志, 2020, 48( 1): 6- 9. DOI: 10.3969/j.issn.2095-8552.2020.01.003.
[18]	SHEN YP, MA HR. Formation mechanism and reduction measures of acrylamide and heterocyclic amine in high temperature cooking[J]. China Food Ind, 2025( 8): 124- 126. DOI: CNKI:SUN:SPZG.0.2025-08-039. 沈雁朋, 马华荣. 高温烹饪中丙烯酰胺与杂环胺的生成机理及消减措施[J]. 中国食品工业, 2025( 8): 124- 126. DOI: CNKI:SUN:SPZG.0.2025-08-039.
[19]	WANG M, WANG ZY, JIANG ZZ, et al. Research progress on the correlation between fatty acid intake and obesity[J]. J Chin Inst Food Sci Technol, 2025, 25( 7): 392- 404. DOI: 10.16429/j.1009-7848.2025.07.034. 王敏, 王子依, 蒋泽祯, 等. 脂肪酸摄入与肥胖的相关性研究进展[J]. 中国食品学报, 2025, 25( 7): 392- 404. DOI: 10.16429/j.1009-7848.2025.07.034.
[20]	FU W, CHENG GB, LYU LY, et al. Association of monounsaturated fatty acid intake with nonalcoholic fatty liver disease risk in Chinese Han adults: A retrospective case-control study[J]. Chin Gen Pract, 2024, 27( 29): 3623- 3628. DOI: 10.12114/j.issn.1007-9572.2024.0147. 付伟, 程国彬, 吕麟亚, 等. 中国汉族成年人群单不饱和脂肪酸摄入量与非酒精性脂肪性肝病风险关系的回顾性病例对照研究[J]. 中国全科医学, 2024, 27( 29): 3623- 3628. DOI: 10.12114/j.issn.1007-9572.2024.0147.
[21]	YANG XX, TANG WG, MAO DQ, et al. Spicy food consumption is associated with abdominal obesity among Chinese Han population aged 30-79 years in the Sichuan Basin: A population-based cross-sectional study[J]. BMC Public Health, 2022, 22( 1): 1881. DOI: 10.1186/s12889-022-14293-4.
[22]	ZHANG SY. The impact of non-alcoholic fatty liver disease on the liver inflammation activity, clinical efficacy of antiviral agents and fibrosis progression in patients with chronic hepatitis B[D]. Shijiazhuang: Hebei Medical University, 2022. DOI: 10.27111/d.cnki.ghyku.2022.000126. 张思雨. 非酒精性脂肪性肝病对慢性乙型肝炎患者肝脏炎症程度、抗病毒治疗应答和肝纤维化进展的影响[D]. 石家庄: 河北医科大学, 2022. DOI: 10.27111/d.cnki.ghyku.2022.000126.
[23]	SHAO CP, XU YQ. Association of serum uric acid-to-creatinine ratio with nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2021, 37( 10): 2348- 2351. DOI: 10.3969/j.issn.1001-5256.2021.10.018. 邵翠萍, 徐有青. 血清尿酸/肌酐比值与非酒精性脂肪性肝病的相关性分析[J]. 临床肝胆病杂志, 2021, 37( 10): 2348- 2351. DOI: 10.3969/j.issn.1001-5256.2021.10.018.
[24]	DING JB, JIN AH, LI XH, et al. The role and mechanism of uric acid in the occurrence and development of nonalcoholic fatty liver disease[J]. Chin Hepatol, 2025, 30( 2): 272- 275. DOI: 10.14000/j.cnki.issn.1008-1704.2025.02.026. 丁剑波, 金爱华, 李秀惠, 等. 尿酸在非酒精性脂肪性肝病发生发展中的作用及机制[J]. 肝脏, 2025, 30( 2): 272- 275. DOI: 10.14000/j.cnki.issn.1008-1704.2025.02.026.
[25]	YIN YY, XIA D, QIAO JR, et al. Correlation analysis of hepatic steatosis, blood lipids and uric acid metabolism in elderly patients with chronic hepatitis B[J]. J Public Health Prev Med, 2023, 34( 1): 144- 147. DOI: 10.3969/j.issn.1006-2483.2023.01.034. 尹袁英, 夏迪, 乔江容, 等. 老年慢性乙型肝炎患者肝脂肪变性与血脂、尿酸代谢的相关性分析[J]. 公共卫生与预防医学, 2023, 34( 1): 144- 147. DOI: 10.3969/j.issn.1006-2483.2023.01.034.
[26]	LYU LN, LI Q, MA WX, et al. Virological features of chronic hepatitis B patients with metabolic associated fatty liver disease: A stratified analysis[J]. J Clin Hepatol, 2024, 40( 7): 1343- 1348. DOI: 10.12449/JCH240710. 吕翎娜, 李琦, 马文霞, 等. 慢性乙型肝炎合并代谢相关脂肪性肝病患者病毒学特征的分层分析[J]. 临床肝胆病杂志, 2024, 40( 7): 1343- 1348. DOI: 10.12449/JCH240710.
[27]	WANG Y, LI JX, WANG SS, et al. The hepatitis B virus promotes the progression of non-alcoholic fatty liver disease through incomplete autophagy[J]. Free Radic Biol Med, 2023, 204: 326- 336. DOI: 10.1016/j.freeradbiomed.2023.05.020.
[28]	ZHANG JX, LING N, LEI Y, et al. Multifaceted interaction between hepatitis B virus infection and lipid metabolism in hepatocytes: A potential target of antiviral therapy for chronic hepatitis B[J]. Front Microbiol, 2021, 12: 636897. DOI: 10.3389/fmicb.2021.636897.
[29]	YIN K, SONG YY, LIU F. Research advances in chronic hepatitis B with metabolic dysfunction-associated steatotic liver disease[J]. J Clin Hepatol, 2024, 40( 12): 2499- 2504. DOI: 10.12449/JCH241221. 殷珂, 宋玉芸, 刘峰. 慢性乙型肝炎合并代谢相关脂肪性肝病的研究进展[J]. 临床肝胆病杂志, 2024, 40( 12): 2499- 2504. DOI: 10.12449/JCH241221.
[30]	WANG DM. Regulation of hepatokine Fetuin B on glucose and lipid metabolism in obesity and its activation mechanism[D]. Xiamen: Xiamen University, 2021. DOI: 10.27424/d.cnki.gxmdu.2021.000320. 王冬梅. 肥胖状态下肝因子Fetuin B对糖脂代谢的调控作用及其激活机制研究[D]. 厦门: 厦门大学, 2021. DOI: 10.27424/d.cnki.gxmdu.2021.000320.
[31]	TAN M, ZHANG H, REN JH, et al. The role of lipid metabolism disorders in non-alcoholic fatty liver disease[J]. Chin J Gastroenterol Hepatol, 2024, 33( 8): 1082- 1086. DOI: 10.3969/j.issn.1006-5709.2024.08.025. 谭明, 张慧, 任吉华, 等. 脂质代谢紊乱在非酒精性脂肪性肝病中的作用概述[J]. 胃肠病学和肝病学杂志, 2024, 33( 8): 1082- 1086. DOI: 10.3969/j.issn.1006-5709.2024.08.025.
[32]	MA XY, CHEN Y, LIU JC, et al. Clinical features and related risk factors of chronic hepatitis B patients with concomitant minimal hepatic steatosis[J]. J Clin Hepatol, 2023, 39( 1): 63- 69. DOI: 10.3969/j.issn.1001-5256.2023.01.010. 马晓艳, 陈云, 刘嘉城, 等. 慢性乙型肝炎患者合并极轻肝脏脂肪变性的临床特征及危险因素分析[J]. 临床肝胆病杂志, 2023, 39( 1): 63- 69. DOI: 10.3969/j.issn.1001-5256.2023.01.010.
[33]	ZHANG XT. Clinical characteristics and the efficacy of short-term antiviral therapy in chronic hepatitis B with fatty liver disease[D]. Shenyang: China Medical University, 2024. DOI: 10.27652/d.cnki.gzyku.2024.000749. 张向桐. 慢性乙型肝炎合并脂肪性肝病的临床特征和短期抗病毒治疗的疗效分析[D]. 沈阳: 中国医科大学, 2024. DOI: 10.27652/d.cnki.gzyku.2024.000749.
[34]	DENG WT. Clinical characteristics of hepatitis B complicated with fatty liver and glucose and lipid metabolism disorders and evaluation of intervention effect of Chinese Medicine[D]. Guangzhou: Guangzhou University of Chinese Medicine, 2022. DOI: 10.27044/d.cnki.ggzzu.2022.000723. 邓文婷. CHB合并NAFLD糖脂代谢紊乱患者的临床特点及中药干预效果评价[D]. 广州: 广州中医药大学, 2022. DOI: 10.27044/d.cnki.ggzzu.2022.000723.
[35]	YANG T, LI J. Chronic hepatitis B comorbid with nonalcoholic fatty liver disease: Contemporary insights and controversies[J]. J Clin Hepatol, 2023, 39( 8): 1797- 1804. DOI: 10.3969/j.issn.1001-5256.2023.08.005. 阳韬, 李军. 慢性乙型肝炎合并非酒精性脂肪性肝病: 当前的认识与争议[J]. 临床肝胆病杂志, 2023, 39( 8): 1797- 1804. DOI: 10.3969/j.issn.1001-5256.2023.08.005.
[36]	JIANG XP, ZHAO H. Effects of nucleos(t)ide analogs on lipid metabolism of patients with chronic hepatitis B[J/CD]. Chin J Liver Dis(Electron Version), 2022, 14( 1): 1- 5. DOI: 10.3969/j.issn.1674-7380.2022.01.001. 蒋晓萍, 赵红. 一线核苷(酸)类药物对慢性乙型肝炎患者脂质代谢的影响[J/CD]. 中国肝脏病杂志(电子版), 2022, 14( 1): 1- 5. DOI: 10.3969/j.issn.1674-7380.2022.01.001.
[37]	CHEN ZJ. Comparison between tenofovir disoproxil fumarate and entecavir on blood lipid profiles in chronic hepatitis B[D]. Fuzhou: Fujian Medical University, 2023. DOI: 10.27020/d.cnki.gfjyu.2023.000452. 陈志坚. 替诺福韦酯与恩替卡韦对慢性乙型肝炎患者血脂谱的不同影响[D]. 福州: 福建医科大学, 2023. DOI: 10.27020/d.cnki.gfjyu.2023.000452.
[38]	ZHANG RJ. Clinical study on sequential treatment with tenofovir alafenamide for chronic hepatitis B treated with entecavir[D]. Shantou: Shantou University, 2022. DOI: 10.27295/d.cnki.gstou.2022.000595. 张若锦. 恩替卡韦经治慢性乙型肝炎患者序贯富马酸丙酚替诺福韦治疗的临床研究[D]. 汕头: 汕头大学, 2022. DOI: 10.27295/d.cnki.gstou.2022.000595.
[39]	CHENG JX, WANG WD, SHI MB, et al. The efficacy and safety analysis of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in the treatment of chronic hepatitis B[J]. Infect Dis Inf, 2024, 37( 1): 11- 15. DOI: 10.3969/j.issn.1007-8134.2024.01.003. 程家喜, 王万党, 石梅彬, 等. 恩替卡韦、富马酸替诺福韦二吡呋酯及富马酸丙酚替诺福韦治疗慢性乙型肝炎的疗效及安全性分析[J]. 传染病信息, 2024, 37( 1): 11- 15. DOI: 10.3969/j.issn.1007-8134.2024.01.003.
[40]	GUO HQ, LI ML, LIU F, et al. Characteristics and lifestyles of patients with metabolic dysfunction-associated fatty liver disease based on the physical examination population[J]. J Clin Hepatol, 2025, 41( 6): 1090- 1096. DOI: 10.12449/JCH250614. 郭海清, 李明亮, 刘峰, 等. 基于体检人群调查代谢相关脂肪性肝病患者特征及生活方式[J]. 临床肝胆病杂志, 2025, 41( 6): 1090- 1096. DOI: 10.12449/JCH250614.
[41]	SONG ST, HUANG RL, CHEN J, et al. Multivariate analysis of the distribution characteristics and influencing factors of traditional Chinese medicine constitution in hyperuricemia: A retrospective study based on 3205 physical examination subjects[J/OL]. J Liaoning Univ Tradit Chin Med, 1- 11[ 2025-07-28]. https://link.cnki.net/urlid/21.1543.R.20250708.1434.010. https://link.cnki.net/urlid/21.1543.R.20250708.1434.010 宋书婷, 黄日龙, 陈军, 等. 高尿酸血症中医体质分布特征及影响因素的多因素分析——基于3205例体检人群的回顾性研究[J/OL]. 辽宁中医药大学学报, 1- 11[ 2025-07-28]. https://link.cnki.net/urlid/21.1543.R.20250708.1434.010. https://link.cnki.net/urlid/21.1543.R.20250708.1434.010
[42]	NAN J, LI SJ, GUO QY, et al. Prevalence and health impact of adult central obesity[J]. J Hyg Res, 2025, 54( 1): 141- 147. DOI: 10.19813/j.cnki.weishengyanjiu.2025.01.025. 南晶, 李淑娟, 郭齐雅, 等. 成人中心型肥胖流行状况及健康影响[J]. 卫生研究, 2025, 54( 1): 141- 147. DOI: 10.19813/j.cnki.weishengyanjiu.2025.01.025.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(8)

Get Citation

PDF

XML

Article Metrics

Article views (54) PDF downloads(22)

Features and risk factors in chronic hepatitis B patients comorbid with metabolic associated fatty liver disease

DOI: 10.12449/JCH251212

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content